Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001012323 | SCV001172756 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-12-05 | criteria provided, single submitter | clinical testing | The p.W532* pathogenic mutation (also known as c.1595G>A), located in coding exon 11 of the CDH1 gene, results from a G to A substitution at nucleotide position 1595. This changes the amino acid from a tryptophan to a stop codon within coding exon 11. This alteration has been identified in an individual with diffuse gastric cancer (Benusiglio PR et al. J. Med. Genet., 2013 Jul;50:486-9). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
European Reference Network on Genetic Tumour Risk Syndromes |
RCV003229609 | SCV003926822 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2022-08-01 | criteria provided, single submitter | clinical testing | PVS1; PS4_Supporting; PM2 (PMID: 30311375) |
Myriad Genetics, |
RCV003229609 | SCV004044830 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2023-06-14 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |